Clinical Trial Update: Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor [Phase 3]

View source ↗

Summary

Phase 3 trial update reports results for telotristat ethyl in treating carcinoid heart disease in patients with metastatic neuroendocrine tumors; results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Heart Disease
• Neuroendocrine Tumor

Drugs mentioned

• Telotristat Ethyl (Xermelo) (telotristat ethyl)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-05